Segall Bryant & Hamill LLC cut its stake in BioTelemetry Inc (NASDAQ:BEAT) by 3.1% in the 4th quarter, Holdings Channel reports. The firm owned 22,993 shares of the medical research company’s stock after selling 725 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in BioTelemetry were worth $1,373,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of BioTelemetry by 2.7% in the fourth quarter. BlackRock Inc. now owns 5,092,773 shares of the medical research company’s stock worth $304,141,000 after purchasing an additional 134,956 shares during the last quarter. Vanguard Group Inc raised its stake in shares of BioTelemetry by 2.8% in the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock worth $122,462,000 after purchasing an additional 52,363 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of BioTelemetry by 2.8% in the third quarter. Vanguard Group Inc. now owns 1,900,117 shares of the medical research company’s stock worth $122,462,000 after purchasing an additional 52,363 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of BioTelemetry by 11.8% in the fourth quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock worth $22,490,000 after purchasing an additional 39,722 shares during the last quarter. Finally, Loomis Sayles & Co. L P purchased a new stake in shares of BioTelemetry in the third quarter worth approximately $23,211,000. 88.91% of the stock is owned by hedge funds and other institutional investors.

Shares of BEAT opened at $61.76 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81. The company has a market cap of $2.08 billion, a P/E ratio of 31.84 and a beta of 1.47. BioTelemetry Inc has a 12 month low of $29.85 and a 12 month high of $80.92.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.13. The company had revenue of $103.60 million during the quarter, compared to the consensus estimate of $102.84 million. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. BioTelemetry’s revenue was up 13.0% on a year-over-year basis. During the same period last year, the business posted $0.32 earnings per share. On average, equities research analysts predict that BioTelemetry Inc will post 1.94 EPS for the current year.

In related news, VP Heather C. Getz sold 93,383 shares of the stock in a transaction that occurred on Tuesday, January 29th. The stock was sold at an average price of $70.06, for a total transaction of $6,542,412.98. Following the completion of the sale, the vice president now directly owns 119,085 shares of the company’s stock, valued at $8,343,095.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Heather C. Getz sold 10,590 shares of the stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $70.41, for a total value of $745,641.90. Following the sale, the vice president now directly owns 80,661 shares of the company’s stock, valued at $5,679,341.01. The disclosure for this sale can be found here. Insiders have sold 177,198 shares of company stock valued at $12,419,736 over the last ninety days. 8.30% of the stock is currently owned by company insiders.

BEAT has been the subject of several analyst reports. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $84.00 price objective for the company in a research note on Thursday, February 28th. BidaskClub downgraded BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 18th. Lake Street Capital set a $90.00 price objective on BioTelemetry and gave the stock a “buy” rating in a research note on Friday, February 22nd. ValuEngine downgraded BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 23rd. Finally, Sidoti set a $95.00 price objective on BioTelemetry and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $75.67.

TRADEMARK VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/segall-bryant-hamill-llc-has-1-37-million-stake-in-biotelemetry-inc-beat/2924221.html.

BioTelemetry Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Read More: Put Option Volume

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.